

Concert Pharmaceuticals to Report First Quarter 2017 Financial Results on May 2, 2017, and Present at Upcoming Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)-- [Concert Pharmaceuticals, Inc.](#) (NASDAQ: CNCE) today announced that it will report its first quarter 2017 financial results on Tuesday, May 2, 2017, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss first quarter financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).

In addition, the Company today announced that it will present a corporate overview at the following upcoming investor conferences:

- | The 42nd Annual Deutsche Bank Securities Health Care Conference on May 3, 2017 at 2:50 p.m. ET in Boston, MA; and
- | The UBS Global Healthcare Conference on May 23, 2017 at 1:30 p.m. ET in New York, NY.

A live webcast of these presentations, including the first quarter financial results, may be accessed in the [Investors](#) section of the Company's website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the first quarter financial results webcast will be available on Concert's website for three months. A replay of the investor conference webcasts will be available on Concert's website for two weeks following each presentation.

About Concert

[Concert Pharmaceuticals](#) is a clinical stage biopharmaceutical company focused on applying its [DCE Platform®](#) (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs. The Company's approach starts with approved drugs in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert has a [broad pipeline](#) of innovative medicines targeting pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170425005151/en/>

Concert Pharmaceuticals, Inc.
Justine Koenigsberg, 781-674-5284
ir@concertpharma.com

Source: Concert Pharmaceuticals, Inc.

News Provided by Acquire Media